Farletuzumab ecteribulin 产品活性：Farletuzumab ecteribulin (MORAb-202) 是一种抗体-活性分子偶联物 (ADC)，由人源化抗人叶酸受体 α (FRA) 抗体 Farletuzumab (HY-P99153) 通过还原的链间二硫键与 Mal-PEG2-Val-Cit-PAB-eribulin 偶联而成。Farletuzumab ecteribulin 的活性分子抗体比为 4.0。Farletuzumab ecteribulin 在体外对 FRA 阳性细胞具有高度细胞毒性。Farletuzumab ecteribulin 具有有效的抗肿瘤活性。 产品来源： https://www.medchemexpress.cn/farletuzumab-ecteribulin.html 研究领域：Antibody-drug Conjugate/ADC Related 作用靶点：Antibody-Drug Conjugates (ADCs) In Vitro: Farletuzumab ecteribulin (MORAb-202; 5.1 pM-10 μM; 5?days) is highly cytotoxic to FRA-positive cells in vitro (IGROV-1: IC50=1 nM, NCI-H2110: IC50=74 nM, A431-A3: IC50=2.3 μM). In Vivo: Farletuzumab ecteribulin (MORAb-202; IV; single injection 1, 5?mg/kg at day 0 or 5?mg/kg every 11 days; 60 days) has a significant antitumor activity with once or twice 5 mg/kg. Farletuzumab ecteribulin (2mg/kg; IV) has a T1/2s of 192 and 162 hours and AUC(0-t)s of 7160 and 6300 ug·h/mL for male and female cynomolgus monkeys on Day 1. 相关产品：Trastuzumab deruxtecan | Trastuzumab emtansine | Sacituzumab govitecan | Disitamab vedotin | Datopotamab deruxtecan | Brentuximab vedotin | Enfortumab vedotin-ejfv | Gemtuzumab ozogamicin | Patritumab deruxtecan | Mirvetuximab soravtansine (solution) | Belantamab mafodotin | Telisotuzumab vedotin | Tusamitamab ravtansine | Polatuzumab vedotin | Labetuzumab govitecan | Loncastuximab tesirine | Tisotumab vedotin | ANG1005 | Glembatumumab vedotin | Trastuzumab duocarmazine | Cantuzumab ravtansine | Cofetuzumab pelidotin | Zilovertamab vedotin | Cantuzumab mertansine | Depatuxizumab mafodotin 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。